Pharming Group (OTCMKTS:PHGUF – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.
Pharming Group Stock Performance
Shares of Pharming Group stock remained flat at $1.25 during mid-day trading on Friday. 5,071 shares of the company’s stock traded hands, compared to its average volume of 390. Pharming Group has a one year low of $0.96 and a one year high of $2.17. The company has a market cap of $836.96 million, a PE ratio of 62.39 and a beta of 0.55. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.65. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.39.
Pharming Group Company Profile
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
Featured Stories
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
